PMID- 19966175
OWN - NLM
STAT- MEDLINE
DCOM- 20100422
LR  - 20131121
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 15
IP  - 1
DP  - 2010 Mar
TI  - Trimetazidine shortens QTc interval in patients with ischemic heart failure.
PG  - 31-6
LID - 10.1177/1074248409354601 [doi]
AB  - BACKGROUND: Trimetazidine improves functional class and left ventricular function 
      in patients with heart failure; however, its potential impact on QTc interval 
      remains undefined. We analyzed the effects of trimetazidine on QTc interval in 
      patients with ischemic heart failure. METHODS: A prospective trial included 42 
      patients with ischemic heart failure (New York Heart Association [NYHA] 2 or 3) 
      and reduced left ventricular ejection fraction (<55%), who were randomly 
      allocated to conventional therapy plus trimetazidine in a modulated release 
      formulation (35 mg twice daily; 22 patients) or conventional therapy alone (20 
      patients; controls). We measured QTc interval at baseline and after 1 month. 
      RESULTS: At baseline, QTc interval duration was similar in both groups (443 +/- 
      41 milliseconds in trimetazidine group vs 446 +/- 27 milliseconds in controls, P 
      = .62). After 1 month, QTc interval decreased in the trimetazidine group (404 +/- 
      36 milliseconds, P = .0002) but not in controls (452 +/- 25 milliseconds, P = 
      .74). QTc interval shortening with trimetazidine was more pronounced in patients 
      with prolonged (>440 milliseconds) baseline QTc interval (-45 +/- 38 
      milliseconds) than in patients with normal QTc interval (-19 +/- 19 milliseconds 
      P = .04). Significant QTc interval shortening (>20 milliseconds) was present in 
      14 of 22 patients (64%) in trimetazidine group compared to 3 of 20 (15%) patients 
      in control group (P = .002). CONCLUSIONS: Trimetazidine therapy is associated 
      with QTc interval shortening in patients with ischemic heart failure.
FAU - Zemljic, Gregor
AU  - Zemljic G
AD  - Advanced Heart Failure and Transplantation Center, Division of Cardiology, 
      Ljubljana University Medical Center, Ljubljana, Slovenia. 
      gregor.zemljic@gmail.com
FAU - Bunc, Matjaz
AU  - Bunc M
FAU - Vrtovec, Bojan
AU  - Vrtovec B
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20091204
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Vasodilator Agents)
RN  - N9A0A0R9S8 (Trimetazidine)
SB  - IM
MH  - Aged
MH  - Angiography
MH  - *Electrocardiography
MH  - Female
MH  - Heart Failure/*drug therapy/*physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*drug therapy/*physiopathology
MH  - Regression Analysis
MH  - Trimetazidine/*pharmacology
MH  - Vasodilator Agents/*pharmacology
MH  - Ventricular Function, Left/drug effects
EDAT- 2009/12/08 06:00
MHDA- 2010/04/23 06:00
CRDT- 2009/12/08 06:00
PHST- 2009/12/08 06:00 [entrez]
PHST- 2009/12/08 06:00 [pubmed]
PHST- 2010/04/23 06:00 [medline]
AID - 1074248409354601 [pii]
AID - 10.1177/1074248409354601 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2010 Mar;15(1):31-6. doi: 10.1177/1074248409354601. 
      Epub 2009 Dec 4.